mCRPC Clinical Trial
Official title:
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05383079 -
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06056791 -
Study of INKmune in Patients With mCRPC (CaRe Prostate)
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT04145375 -
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04729114 -
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02266745 -
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
|
Phase 2 | |
| Recruiting |
NCT05413850 -
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05340374 -
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01818986 -
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
|
Phase 2 | |
| Not yet recruiting |
NCT04822961 -
Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment
|
Phase 2 | |
| Recruiting |
NCT05547061 -
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03851640 -
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
|
Phase 3 |